Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nonfunctioning adenomas of the pituitary

A Liuzzi1, V Tassi, M T Pirro

  • 1Division of Endocrinology Research Laboratory, Casa Sollievo della Sofferenza Hospital, IRCCS, San Giovanni Rotondo, Italy.

Metabolism: Clinical and Experimental
|August 1, 1996
PubMed
Summary

Nonfunctioning pituitary adenomas (NFPA) are diverse tumors often presenting with visual issues. Differentiating them from prolactinomas is crucial for treatment, with the thyrotropin-releasing hormone (TRH) test being invaluable.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET).

ESMO open·2025
Same author

Molecular tumour board in gastrointestinal cancers.

ESMO open·2025
Same author

Inflammation-based scores in a large cohort of adrenocortical carcinoma and adrenocortical adenoma: role of the hormonal secretion pattern.

Journal of endocrinological investigation·2024
Same author

Diagnosis and treatment of Paget's disease of bone: position paper from the Italian Society of Osteoporosis, Mineral Metabolism and Skeletal Diseases (SIOMMMS).

Journal of endocrinological investigation·2024
Same author

Achievement of Target Gain Larger than Unity in an Inertial Fusion Experiment.

Physical review letters·2024
Same author

Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe.

ESMO open·2023

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Nonfunctioning pituitary adenomas (NFPA) are clinically defined by tumor mass, leading to heterogeneity.
  • Common symptoms include visual impairment and hypogonadism, despite gonadotropin secretion.
  • Distinguishing NFPA from prolactinomas is critical due to differing therapeutic strategies.

Purpose of the Study:

  • To explore the heterogeneous nature of NFPA.
  • To clarify diagnostic and etiological aspects of NFPA.
  • To evaluate potential therapeutic targets and approaches for NFPA.

Main Methods:

  • Clinical definition and diagnostic criteria for NFPA and prolactinomas.
  • Assessment of hormone levels (prolactin, gonadotropins) and response to stimulation tests (TRH, GnRH).

Related Experiment Videos

  • Analysis of tumor origin via immunohistochemistry and investigation of genetic mutations (p53, Rb, nm23) and protein expression (PCNA, PKC).

    • Main Results:

    • NFPA diagnosis relies on mass effect, often with visual and hormonal deficits.
    • The TRH test is valuable for NFPA assessment, unlike GnRH response.
    • Immunohistochemistry indicates most NFPA originate from gonadotroph cells, with some expressing glycoprotein hormones.
    • Genetic mutations and protein abnormalities are linked to aggressive and invasive NFPA.
    • Silent adenomas can present as clinical NFPA.
    • Pharmacological agents (dopamine agonists, octreotide, GnRH analogs) show modest tumor shrinkage (11-20%).

    Conclusions:

    • NFPA are heterogeneous, with diverse origins and genetic underpinnings.
    • Accurate diagnosis, including differentiation from prolactinomas using TRH tests, is essential.
    • While pharmacological treatments offer some benefit, surgery remains the primary therapeutic option for NFPA.